Browns Pharma Holdings plc reported a staggering 72 per cent increase in profit before tax in its six-month interim financial statements released today.

While profits before tax were at €1.89 million for the same time period last year, the first half of 2025 saw the group report €3.27 million in profit before tax, a 72 per cent increase. 

The group works in the retail pharmacy industry where it operates 29 pharmacies around Malta. The parent company holds shares in three subsidiary companies registered in Malta, Brown’s Pharma Limited, JP Pharma Retail Holdings Limited and Brown’s Pharma IP Limited and one subsidiary company registered in the United Kingdom, Mediva Pharma Limited. 

During the first six months of 2025, the group’s revenue amounted to €37 million, an increase of €14.85 million, or 40 per cent, over the comparative period in 2024. Consolidated operating profit amounted to €3.94 million  (2024: €2.55 million)

Browns Pharma Holdings plc continued to grow its Malta operation, Brown’s Pharma Ltd, organically, a statement said, and has experienced significant growth in its UK operation, Mediva Pharma Ltd.

As at 30th June 2025, the group’s total assets amounted to €107,403,497.

During the six months it also acquired property, plant and equipment, with a cost of €534,013 (six months ended 30 June 2024: €376,756)  as well as acquired intangible assets, with a cost of €56,188 (six months ended 30 June 2024: €2,110,120).

By virtue of a prospectus dated 10th June 2021, Brown’s Pharma Holdings plc issued €13,000,000 unsecured bond with a nominal value of €100 each. The bonds have a coupon interest of 3.9 per cent which is payable annually in arrears on 9th July of each year.

The bonds are redeemable at par and are due for redemption between 2027 and 2031, unless they are previously re-purchased and cancelled or redeemed in the case of an early redemption or a partial conditional early redemption.